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Entry of HIVand SIV into susceptible cells is mediated by CD4 and chemokine receptors, which act as coreceptors. To study cell entry of
SIV, we constructed a cell line, xKLuSIV, derived from non-susceptible human K562 cells, that express the firefly luciferase reporter gene
under control of a minimal SIV long terminal repeat (LTR). Using these susceptible cells, we studied the entry of a well-characterized
molecularly cloned macrophage-tropic SIV. xKLuSIV cells that express rhesus macaque CD4 and/or the rhesus chemokine receptor CCR5
are susceptible to infection with the macrophage-tropic, neurovirulent strain SIV/17E-Fr, but only xKLuSIV cells expressing both CCR5 and
CD4 were susceptible to infection by the macrophage-tropic, non-neurovirulent strain SIV/17E-Cl. CCR5-dependent, CD4-independent
infection by SIV/17E-Fr was abrogated by pre-incubation of the cells with AOP-RANTES, a ligand for CCR5. In addition to viral entry
occurring by a CD4-independent mechanism, neutralization of SIV/17E-Fr with rhesus mAbs from 3 different neutralization groups blocked
entry into xKLuSIV cells by both CD4-dependent and -independent mechanisms. Triggering the env glycoprotein of SIV-17EFr with soluble
CD4 had no significant effect in infectivity, but triggering of the same glycoprotein of SIV/17E-Cl allowed it to enter cells in a CD4-
independent fashion. Using mutant molecular clones, we studied the determinants for CD4 independence, all of which are confined to the env
gene. We report here that truncation of the TM at amino acid 764 and changing a single amino acid (R751G) in the SIV envelope
transmembrane protein (TM) conferred the observed CD4-independent phenotype. Our data suggest that the envelope from the neurovirulent
SIV/17E-Fr interacts with CCR5 in a CD4-independent manner, and changes in the TM protein of this virus are important components that
contribute to neurovirulence in SIV.
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Human immunodeficiency virus types 1 and 2 (HIV-1
and HIV-2) are the etiologic agents of AIDS (Barre-Sinoussi
et al., 1983; Gallo et al., 1984). HIV infection has been
found in some cases to degenerate into a neurological
disease associated with encephalitis and dementia, a
pathological consequence called AIDS dementia complex
(ADC), in 25% of cases (Gendelman et al., 1997; Gonzalez-
Scarano and Martin-Garcia, 2005; Wilkie et al., 1992).
Simian immunodeficiency viruses (SIVs), close relatives of
HIV, cause similar immune deficiencies (Desrosiers, 1990)005) 12 – 23
Fig. 1. Maps of the 3V regions of the genomes of SIV/17E-Cl and SIV/17E-
Fr. The molecular clone SIV/17E-Cl was constructed by shuttling the SU
region of the env gene from the previously described neurovirulent SIV/
17E-Br (black bars) into the genetic background of the non-neurovirulent
SIVmac239 (white bars; Flaherty et al., 1997). SIV/17E-Fr differs in that it
also contains the entire env and nef genes of SIV/17-Br (black bars) in the
genetic context of SIVmac239 (white bars; Flaherty et al., 1997), including
TM and part of the 3V LTR. The TM of SIV/17E-Fr contains one mutation
that codes for an R751G change (*) and a second mutation that results in a
truncated envelope glycoprotein at amino acid 763 (open triangle). The
dark diamond represents a stop codon, present in the nef gene of SIV/17E-
Cl to create a truncated nef, but absent in the genome of SIV/17E-Fr, which
expresses a full-length nef (Flaherty et al., 1997).
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non-human primates.
Invasion of the central nervous system (CNS) is crucial
in HIV pathogenesis since resident infected macrophages
and microglia are strong determinants of long-term viral
persistence in the brain; studies in macaques strongly
suggest that the CNS, and these cells in particular, is a
reservoir for SIV (Clements et al., 2002, 2005; Pierson et al.,
2000). Neuroinvasion, persistence, and neuropathogenesis
in AIDS also remain important fields of study because
highly active antiretroviral therapy does not adequately
reach the CNS (Pierson et al., 2000; Siliciano, 1999).
HIV/SIVentry into target cells is mediated by a multistep
mechanism that is facilitated by interactions between the
virus surface glycoproteins and cellular receptors. Typically,
the first requirement is the binding of the virus gp120 to its
cellular receptor, CD4 (Dalgleish et al., 1984; Klatzmann et
al., 1984; Maddon et al., 1986; McDougal et al., 1986). The
interaction of these two proteins triggers a series of
conformational changes in gp120 that results in the
exposure of the coreceptor binding site (Edinger et al.,
1999; Wu et al., 1996). These coreceptors for HIV and SIV
are members or close relatives of the chemokine receptor
subfamily of G protein-coupled receptors (Horuk, 2001);
one major coreceptor for HIV-1, HIV-2, and SIV is the
chemokine receptor CCR5 (Alkhatib et al., 1996; Chen et
al., 1997; Deng et al., 1996; Doranz et al., 1996; Edinger et
al., 1997a; Marcon et al., 1997; Rucker et al., 1997; Rucker
et al., 1996). Binding of gp120 to the coreceptor is believed
to trigger an additional conformational change that allows
gp41 to fuse the viral and cellular membranes, allowing the
virus to enter the cell (Chan et al., 1997; Weissenhorn et al.,
1997).
Although the interaction between gp120 and CD4 is
required for HIV/SIV entry for most cases, infection of cells
devoid of CD4 has been reported as well. Some HIV isolates
have been adapted in vitro or have spontaneously changed
to enter susceptible cells via a CD4-independent pathway,
including those viruses that utilize CCR5 and/or CXCR4 in
a CD4-independent manner (Azevedo-Pereira et al., 2003;
Dumonceaux et al., 1998; Hoxie et al., 1998; Kolchinsky et
al., 1999; LaBranche et al., 1999; Lin et al., 2003; Liu et al.,
2000; Zerhouni et al., 2004a, 2004b). No CD4-independent
isolates of HIV have been found in vivo, perhaps because
CD4-independent viruses are readily neutralized by circu-
lating antibodies (Edwards et al., 2001; Kolchinsky et al.,
2001; Means et al., 2001; Thomas et al., 2003). Several SIV
strains have also been reported to enter via a CD4-
independent CCR5-dependent pathway (Bhattacharya et
al., 2003; Edinger et al., 1997b; Liu et al., 2000; Pohlmann
et al., 2004; Puffer et al., 2004; Vodros et al., 2003),
suggesting that CD4 utilization is a more recently acquired
activity of the envelope glycoprotein during the evolution of
the immunodeficiency viruses (Martin et al., 1997).
CCR5, particularly when expressed by macrophages and
microglia, seems to be the coreceptor cited as being utilizedmost often by neurotropic HIVs (Albright et al., 1999;
Ghorpade et al., 1998b; He et al., 1997; Shieh et al., 1998).
All strains of SIV utilize CCR5 as a coreceptor and
neurotropic isolates of SIV can do so in a CD4-independent
fashion (Edinger et al., 1997b). This activity is in contrast to
the SIVs found in the periphery of the same hosts, where
absolute CCR5 reliance and CD4 independence vary
considerably (Babas et al., 2001; Korber et al., 1994;
Shapshak et al., 1999). It therefore appears that evolution of
the virus in the CNS and in the periphery is different and
independent, but any mechanisms for specific neuroinvasion
and receptor interaction by the CD4-independent viruses has
yet to be elucidated.
To begin investigating mechanisms of CD4 independ-
ence, we have taken advantage of previous studies
demonstrating variations in neurotropism exhibited by
different infectious molecular clones of SIV (Flaherty et
al., 1997; Mankowski et al., 1997). The transmembrane
domain of the SIV envelope protein was shown in these
studies to play a role in SIV pathogenesis; sequence analysis
from a neurotropic SIV molecular clone derived from a
brain isolate (SIV/17E-Fr) suggested that TM and nef may
play a role in neurotropism (Barber et al., 1998; Flaherty et
al., 1997, 1998). We therefore investigated the role of
mutations in TM and Nef in the infection of cells by the
neurotropic virus SIV/17E-Fr and its possible implications
in the CD4-independent mechanism previously observed.Results
Creation of xKLuSIV cell lines
To study SIV usage of chemokine receptors for cell entry
by simian immunodeficiency viruses of different tropisms,
we used the K562 human chronic myelogenous leukemia
cell line that has been used extensively in chemokine
receptor experiments because it expresses few, if any,
Table 1
Percentage of cells expressing cell surface receptors
Cell type Receptor
CD4 CCR5 CD4 and CCR5
xKLuSIV 0.7 0.5 NA
xKLuSIV-RhCD4 29.0 NA NA
xKLuSIV-RhCCR5 NA 30.0 NA
xKLuSIV-RhCD4/CCR5 27.0 56.0 25.0
Percentages calculated over background (binding of irrelevant isotype
control) by flow cytometry.
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utilized for SIV or HIV entry (Baba et al., 1997; Gao and
Murphy, 1995). We stably transformed a reporter construct,
pLuc (Roos et al., 2000), into K562s to create a parental cell
line, xKLuSIV, that could be used to readily identify cells
that were infected by a straightforward, quantitative
luciferase assay (Roos et al., 2000). Transfection of an
infectious molecular clone into xKLuSIV cells resulted in
activation of the luciferase gene (Fig. 3A), while inoculating
the same cells with virus from either the macrophage-tropic
non-neurovirulent SIV/17E-Cl or with the macrophage-
tropic neurovirulent SIV/17E-Fr (see Fig. 1 for env maps of
these two strains) resulted in no detectable luciferase
activity (Fig. 3B); neither virus’ replication was detected
in basic xKLuSIV cells 4 days post-inoculation. These data
showed that the basic xKLuSIV cells were devoid of any
functional cellular receptors for SIV, but that they also had
all the necessary intracellular components to support
replication. xKLuSIV cells were then transformed withFig. 2. Expression of receptors on the surface of xKLuSIV cells as quantitated by f
of CD4. Staining on xKLuSIV cells is depicted in parts A and C; staining on xK
stained in part D; xKLuSIV-RhCD4/CCR5 cells are stained in part E. Cells were
(clone 182F, R&D Systems) and/or human CD4 (clone Leu3a, Becton-Dickinson) aeither or both RhCD4 and RhCCR5 cDNA. Each cell line
bearing different receptors was drug selected and each
molecule’s surface expression was confirmed by flow
cytometry, (Table 1 and Fig. 2; see Materials and methods).
Infection of xKLuSIV cells with SIV/17E-Fr and SIV/17E-Cl
SIV/17E-Fr has been shown to productively infect rhesus
brain-derivedmicrovascular cells as well as astrocytes devoid
of CD4 via CCR5 (Edinger et al., 1997b; Mankowski et al.,
1994; Overholser et al., 2005). To determine whether SIV/
17E-Fr could use CCR5 in a CD4-independent manner in our
system, xKLuSIV cells expressing the various receptor
combinations were infected and luciferase activity was
measured 4 days post-inoculation. xKLuSIV cells expressing
CCR5, regardless of CD4 expression, supported replication
of SIV/17E-Fr (Fig. 3B); xKLuSIV cells expressing no
receptor or CD4 alone were refractory to infection (Fig. 3B),
indicating that no other alternative coreceptor is available in
the cells that can be utilized for entry in a CD4-dependent
manner. Similar experiments with SIV/17E-Cl showed that
this latter virus can infect only those xKLuSIV cells that
express both CD4 and CCR5 (Fig. 3B), demonstrating this
virus’ absolute dependence on both the receptor and
coreceptor for entry. These data also show that, given the
same SU gene (Fig. 1), there is a clear difference in each
virus’ ability to use CCR5 in a CD4-independent manner; SU
is not a determinant for CD4 independence in these viruses. It
should also be noted that SIV/17E-Fr infection of xKLuSIV-
RhCCR5/CD4 cells resulted in an approximately tenfoldlow cytometry. (A, B, and E) Expression of CCR5; (C, D, and E) expression
LuSIV-RhCCR5 cells is depicted in part B; xKLuSIV-RhCD4 cells were
stained with the indicated monoclonal antibodies specific for human CCR5
nd their respective mAb isotype controls (data not shown). See also Table 1.
Fig. 3. (A and B) SIV/17E-Cl (white bars) and SIV/17E-Fr (black bars)
replication assayed as luciferase activity in xKLuSIV cells expressing
CCR5, CD4, CCR5, and CD4, or no receptors. (A) Virus replication at
2 days post-transfection of 10 Ag of viral cDNA for SIV/17E-Fr as an
infectious molecular clone. (B) Virus replication at 4 days post-inoculation
with 1.9  104 cpm of RT of virus. (C) AOP-RANTES blocks CCR5-
mediated entry of SIV/17E-Fr. Cells were pretreated with AOP-RANTES at
0, 250, or 500 ng/mL for 1 h, then inoculated with SIV/17E-Fr. Virus was
removed after 16 h, fresh AOP-RANTES was added to the cultures (see
Materials and methods), then progeny were quantitated with a p27 assay 4
days post-inoculation. Viral growth is denoted as a percentage of p27
produced when cells were not pre-incubated with AOP-RANTES. Data are
reflective of one assay that was chosen as representative of at least 3
independently conducted trials.
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observation is consistent with previous data that showed
CD4-dependent usage of CCR5 by the envelope of SIV/17E-
Fr was higher than its CD4-independent usage of the same
molecule (Edinger et al., 1997b).
AOP-RANTES blocks SIV/17E-Fr infection
As further confirmation that the CD4-independent entry
observed in xKLuSIV cells was mediated only by CCR5,
xKLuSIV cells expressing RhCCR5 were infected with
SIV/17E-Fr in the presence or absence of a CCR5 ligand
that blocks infection, AOP-RANTES. AOP-RANTES has
been shown to inhibit virus infection approximately tenfold
more efficiently than wild-type RANTES while not induc-
ing most of the cellular responses (e.g., chemotaxis)
normally associated with RANTES-induced cellular activa-
tion (Mack et al., 1998; Proudfoot et al., 1999; Rodriguez-
Frade et al., 1999; Signoret et al., 2000; Simmons et al.,
1997; Vila-Coro et al., 1999). Pre-incubation of xKLuSIV
CCR5 cells with 250 or 500 ng/mL of AOP-RANTES
resulted in >95% inhibition of SIV/17E-Fr infection,
suggesting that virus entry into these cells is CCR5-
dependent (Fig. 3C). It should also be noted that progeny
in these experiments were assayed by p27 quantitation; this
measurement provided evidence that xKLuSIV cells did not
just signal the presence of entering virus by luciferase, but
supported production of viable progeny that finished a
complete replication cycle.
Soluble CD4 (sCD4) triggering of gp120
The envelope glycoprotein of primate lentiviruses has
been shown to undergo a dramatic conformational change
upon binding CD4 that permits binding to the coreceptor
CCR5 (Trkola et al., 1996). The CD4 independence of SIV/
17E-Fr entry, then, may be the result of an already partially
triggered conformation of this virus’ envelope, whereas the
envelope of the CD4-dependent SIV/17E-Cl may still exist
in an unchanged form. Therefore, to test whether the
interaction of the viral glycoproteins with CCR5 in the
absence of CD4 could be improved by pre-triggering gp120
with sCD4, SIV/17EFr and SIV/17E-Cl were pre-incubated
with different amounts of sCD4 and an infectivity assay was
performed. Triggering of SIV/17E-Fr with sCD4 facilitated
only marginally increased efficiency of entry into cells
expressing either CCR5 alone or CCR5 with CD4, but did
not allow entry into cells expressing only CD4 (Fig. 4A).
Triggering SIV/17E-Cl with sCD4 allowed a small amount
of the virus to enter CD4-negative, CCR5-positive cells
(Fig. 4B), albeit not to the same level as was seen with SIV/
17E-Fr without triggering (Fig. 4A). As was observed with
SIV/17E-Fr, triggering also did not permit SIV/17E-Cl to
enter cells expressing only CD4 (Fig. 4B). Interestingly,
increasing concentrations of sCD4 slightly inhibited infec-
tion of cells expressing both CCR5 and CD4 (Fig. 4), a
Fig. 4. Effects of sCD4 on SIV infection. SIV/17E-Fr (A) and SIV/17E-Cl (B) were pre-incubated with 0, 1, 5, or 10 Ag/mL sCD4 for 1 h at 37 -C (see
Materials and methods). Four days after inoculation with the pretreated viruses, viral growth was assayed by quantitation of p27 in the tissue culture medium.
Infection was compared in xKLuSIV cells expressing either CCR5, CD4, or both receptors. Data are reflective of one assay that was chosen as representative of
at least 3 independently conducted trials.
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attributed to direct competition for virus attachment to
CD4 on target cells (Allan et al., 1990; Clapham et al.,
1992; Schutten et al., 1995; Sullivan et al., 1998). These
data suggest that the envelope of SIV/17E-Fr naturally
exposes the coreceptor binding site, and that CD4 binding is
not required to induce the first conformational changes
needed to bind CCR5.
SIV/17E-Fr neutralization with anti-SIV rhesus mAbs
Antibody neutralization of a virus, a phenomenon that
can occur at binding, entry, or post-entry events, prevents
productive infection of a cell. To examine the roles of both
CD4 and the coreceptor CCR5 in SIV/17E-Fr infection,
neutralizing mAbs were employed in a traditional neutral-
ization assay. Rhesus neutralizing mAbs that recognize the
SU portion of the neurovirulent virus SIV/17E-Br and theSIV/17E-Fr envelope glycoprotein were originally raised
against an SIV/17E-Cl inoculum (Cole et al., 2001). These
antibodies efficiently neutralize SIV/17E-Cl and other SIVs,
but are unable to inhibit the CD4–gp120 interaction of
SIVmac239 (Cole et al., 2001). Hence, the antibodies may
neutralize infection by obscuring another cell surface
interaction, most likely at the coreceptor (i.e., CCR5)
binding site of the envelope protein (Cole et al., 2001). To
examine whether the mAbs would neutralize infectivity of
SIV/17E-Fr independently of CD4, we utilized xKLuSIV
cells to determine the relative neutralization abilities of these
antibodies for both CD4-dependent and CD4-independent
CCR5 usage with SIV/17E-Fr.
Three mAbs, 4.7A, 3.11E, and C26, which are specific
for conformation-dependent epitopes and belong to the three
different competition groups V, VI, and VII, respectively
(Cole et al., 2001), were examined. CCR5 utilization by
SIV/17E-Fr was efficiently neutralized when the virus was
Table 2b
Neutralization titer (log10) of monoclonal antibodies
a
mAb Cell type
xKLuSIV-RhCCR5 xKLuSIV-RhCCR5/CD4
4.7A 4.55 3.85
3.11E 3.85 3.15
C26 4.55 4.55
a 50% neutralization endpoint (NP50).
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whether entry was CD4-independent (Tables 2a and 2b,
column 1) or CD4-dependent (Tables 2a and 2b, column 2).
These data suggest that both CD4-independent and CD4-
dependent usage of CCR5 for entry require common regions
of gp120 that are subject to neutralization. The requirement
for lesser amounts of mAb to neutralize CD4-independent
infection (Tables 2a and 2b) may be due to the overall lower
efficiency of CD4-independent CCR5-dependent entry by
SIV/17E-Fr (Fig. 3B); a less efficient entry scheme is most
likely more easily neutralized than a more efficient CD4-
dependent one.
Mapping the determinants for CCR5-dependent
CD4-independent entry of SIV/17E-Fr
To determine which portions of the 3V end of the SIV
genome confer CD4-independent utilization of CCR5, we
employed the parental strains SIV/17E-Cl and SIV/17E-Fr
(Fig. 1) and their derivatives, 17E-FrDNef, 3–11, 3–11 R–
G, 3–7, and 4–1 (Fig. 5) (Flaherty et al., 1997). Each of
these recombinants contains different components of the
region 3V of the SU gene, which was found not to be an
important determinant of CD4-independent CCR5 utiliza-
tion (Figs. 1 and 3). xKLuSIV CCR5 cells provided a
system to test the relative ability of each virus to utilize
CCR5 alone for entry, in the absence of CD4.
One major difference between SIV/17E-Cl and SIV/17E-
Fr lies in the nef gene (Fig. 1); SIV/17E-Cl codes for a
truncated protein, while SIV/17E-Fr codes for a full-length
nef. To determine whether expression of this full-length
gene conferred CD4-independent CCR5-usage, the
recombinant 17E-FrDNef (with the coding sequence for
nef deleted, yet with all other SIV/17E-Fr genes intact) was
utilized to infect xKLuSIV CCR5 cells (Fig. 5). Although
infection was slightly abrogated using the 17E-FrDNef virus
(Fig. 5), there was still approximately 70% of the infection
rate with this virus relative to SIV/17E-Fr (Fig. 5). These
data strongly suggest that nef is not required for CD4
independence, evidence that is further corroborated by high
levels of CD4-independent infection with recombinant 4–1,
which also encodes a truncated nef (Fig. 5).
A second difference between SIV/17E-Cl and SIV/17E-
Fr, the presence of a prematurely truncated TM (Fig. 1), was
analyzed in the same assay (Fig. 5). Although not the sole
determinant of CD4-independent CCR5 usage, the truncatedTable 2a
Amount of mAb (ng) required to neutralize SIV/17E-Fr
mAb Cell type
xKLuSIV-RhCCR5 xKLuSIV-RhCCR5/CD4
4.7A 2.6 64
3.11E 0.5 64
C26 0.5 13
Quantities reflect the amount of antibody required to completely prevent
virus, as assayed by release of p27 (see Materials and methods).TM present in SIV/17E-FrDNef and the 4–1 recombinant
displays enhanced CD4-independent functionality (Fig. 5),
no less than 60% of the activity conferred by SIV/17E-Fr’s
truncated TM. The 3–11 and 3–7 recombinants, which lack a
truncated TM and differ in only the origin of their nef genes,
utilized CCR5 negligibly in a CD4-independent fashion (Fig.
5), although the 3–11 R–G recombinant still showed
approximately 40% of that function when compared to
SIV/17E-Fr. Repeated attempts to create an infectious
molecular clone with only the truncated TM, to permit
examining its importance without other potential confound-
ing factors (e.g., the R751G change), were unsuccessful;
therefore, we must rely on these data alone to prove the
importance of a truncated TM. Our experiments further
reinforce the irrelevance of nef with respect to CD4-
independent infection, and also strongly suggest that a
truncated TM, although not the sole determinant of CD4
independence, is a significant contributing factor.
The last major difference between SIV/17E-Fr and SIV/
17E-Cl, a single R-to-G change at amino acid 751 in the TM,
was analyzed primarily through the use of recombinants 3–
11 and 3–11 R–G for infection of xKLuSIV CCR5 cells
(Fig. 5). The single point mutant in 3–11 at amino acid 751
in the TM, called 3–11 R–G, restored CD4-independent
infection to at least 40% of the level of that shown by SIV/
17E-Fr (Fig. 5), proving that this single amino acid change
was very important for CD4-independent CCR5 usage;
absence of the R-to-G change results in a completely CD4-
dependent phenotype for recombinant 3–11. Data generated
with the 4–1 and 17E-FrDNef recombinants provided
further proof of the R-to-G importance because each of
these viruses expressing the R571G change displayed CD4-
independent infection (Fig. 5); another virus lacking the
R-to-G change, 3–7, showed no CD4-independent CCR5
usage (Fig. 5). These data suggest that the R751G change is
absolutely necessary for CD4-independent infection.
These data taken together demonstrate that a truncated
TM and R751G change are most likely the major and
perhaps the sole determinants required to confer CD4-
independent CCR5 usage to the SIV/17E-Fr strain, and that
nef is not implicated this mechanism.Discussion
It was previously shown that the complete recombinant
envelope glycoprotein of SIV/17E-Fr was able to fuse with
Fig. 5. Determinants of CD4-independent CCR5 usage in the TM. xKLuSIV-RhCCR5 cells (1.25  105) were inoculated with 1.875  103 cpm SIV/17E-Cl,
SIV/17E-Fr, and recombinant viruses created from both (Flaherty et al., 1997). Virus growth was detected by luciferase assay 4 days post-inoculation, as
described in Materials and methods and was normalized to luciferase activity from infection with SIV/17E-Fr (100%). The black bars in the right of the figure
indicate sequences derived from the genome of SIV/17E-Fr; the white bars, those from SIVmac239. A triangle marks the truncation in TM; asterisks the R-to-G
mutation; black diamonds the truncated nef. Mock inoculation resulted in 10% of the luciferase activity generated from SIV/17E-Fr infection, and was drawn
as the dotted baseline in the left figure. Data are reflective of one assay that was chosen as representative of at least 3 independently conducted trials.
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al., 1997b). We extended that work here by using our novel
assay, xKLuSIV cells devoid of any natural chemokine
receptors, to emphasize that point in a whole virus–whole
cell system; as shown in Fig. 3, live SIV/17E-Fr was able to
infect CCR5-positive, CD4-negative cells, while SIV/17E-Cl
was not. Such CD4-independent usage of CCR5 may be
relevant to CNS infection because it appears that neurotropic
HIVs and SIVs, including our neurotropic SIV/17E-Fr, use
CCR5 in the brain as a primary receptor in cells expressing
little to no CD4 (even though CXCR4 might also be
implicated) (Albright et al., 1999; Ghorpade et al., 1998a,
1998b; Gorry et al., 2001; He et al., 1997). We would propose
that using CCR5 as a primary receptor without CD4 is not
without precedent among lentiviruses, as FIV has been
shown to utilize a single receptor other than an immunoglo-
bulin family member for entry (Frey et al., 2001).
Infection of the brain is supported essentially by microglia
and resident macrophages (Gonzalez-Scarano and Martin-
Garcia, 2005;Williams andHickey, 2002), cells which express
very low levels of CD4 (Bannert et al., 2000;Mori et al., 2000).
Although neurotropic HIVs and SIVs are capable of infecting
these cells, this by no means implies that these viruses
absolutely shun the use of CD4. SIV/17E-Fr infects cells
muchmore easilywhen providedwithCD4 (Fig. 3), a property
shared with other strains that are capable of using CCR5 in a
CD4-independent fashion; these viruses appear to develop an
even higher affinity for CD4 than strains that exhibit strictly
CD4-dependent entry (Schenten et al., 1999). In our case,
sCD4 had no significant effect on the CD4-independent,
CCR5-dependent entry of SIV/17E-Fr (Fig. 4), suggesting that
this virus has evolved to express a highly stable conformation
of gp120 with a post-triggered-like conformation.We also found that SIV/17E-Fr was highly sensitive to
neutralization with anti-SIV mAbs (Table 2). These data are
consistent with other reports that have shown that CD4-
independent viruses are typically highly sensitive to neutral-
ization (Edwards et al., 2001; Means et al., 2001; Thomas et
al., 2003). In this study, we used rhesus mAbs generated from
an SIV-infected macaque. SIV/17E-Fr was much more
sensitive to neutralization when used to infect cells devoid
of CD4 instead of infecting cells expressing CD4. We also
found that viruses triggered with CD4 required significantly
lower amounts of neutralizing antibody to abrogate infection
(data not shown). Therefore, CD4-independent viruses,
exposing partially triggered conformations of gp120, appear
to be an easy target for the immune system, implying that
there exists selective pressure against the generation of CD4-
independent viruses in nature. Perhaps these viruses only
have a chance to replicate to high levels in a more terminal
phase of AIDSwhen viral replication in the CNS returns to an
active state (Clements et al., 2002).
Previous studies demonstrated that the envelope gene of
SIV, specifically the region encoding SU, is the sole
determinant for macrophage tropism (Anderson et al.,
1993; Banapour et al., 1991a, 1991b). Further studies have
also demonstrated that while macrophage-tropism is neces-
sary for replication of SIV in the CNS, it is not sufficient
(Mankowski et al., 1997). Comparison of infectious molec-
ular clones, SIV/17E-Fr (Flaherty et al., 1997) and SIV/17E-
Cl, a macrophage-tropic, non-neurovirulent virus (Mankow-
ski et al., 1997) provided evidence that the differences in the
phenotype of these two infectious molecular clones were in
the TM-encoding region of the env gene and the nef gene.
Relatively few studies have addressed the role of the
transmembrane protein in pathogenesis. Our data (Fig. 5)
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confer CD4 independence and that nef is not implicated in
this mechanism. Although there are many CD4-independent
strains of HIV and SIV that have been published (Bhatta-
charya et al., 2003), most of the determinants for this
phenotype have been mapped to other regions of the
genome (Lin et al., 2001). Our data agree with a previous
study that demonstrated changes in the TM which allowed
HIV-2 to enter cells CD4-independently, presumably by
lowering the threshold for gp120 to be triggered and to
induce conformational changes necessary for fusion and
entry (Reeves and Schulz, 1997). It was also clear that the
two aforementioned apparently minor differences between
SIV/17E-Fr and SIV/17E-Cl confer both CD4 independence
and neurovirulence, suggesting that acquisition of mutations
to create differently pathogenic lentiviruses may occur
relatively easily. Our data also imply that minor mutations
to lentiviruses growing in vivo create significant tropic
differences that correlate with a lack of CD4 necessity,
factors that we are just beginning to understand. Our data
are further supported by current studies in our laboratory
using primary rhesus macaque astrocytes; the truncated TM
and R751G mutation in env are also required for the CD4-
independent entry of SIV/17E-Fr into these important cells
of the central nervous system (Overholser et al., 2005).
Analyses of these mechanisms of CNS pathology induced
by HIV and SIV are therefore warranted to design more
efficient retroviral therapies and therapeutic vaccines to
combat these rapidly evolving viruses.Materials and methods
Cells and viruses
K562 cells (ATCC CCL-243; Rockville, MD) were
propagated as previously described (Gao and Murphy,
1995) in R10 medium [RPMI-1640 (Invitrogen-Life Tech-
nologies, Grand Island, NY) containing 10% fetal bovine
serum (FBS; Atlanta Biologicals, Norcross, GA), 10 mM
HEPES, 2 mM glutamine, and 4 Ag/mL gentamicin
(Invitrogen-Life Technologies)]. CEMx174 cells were pre-
pared and propagated in R10 as previously described
(Flaherty et al., 1997; Roos et al., 2000). Plasmids encoding
infectious molecular clones of simian immunodeficiency
viruses, derived as recombinants between SIV/17E-Br, SIV/
17E-Fr, and SIV/17E-Cl (Fig. 1) (Flaherty et al., 1997),
were transfected into CEMx174 cells as described to create
stocks of infectious virus (Anderson et al., 1993; Flaherty et
al., 1997). Virus stocks were standardized by reverse
transcriptase activity (Flaherty et al., 1997).
Plasmids
The plasmids encoding the rhesus macaque CCR5
[pRhCCR5, in the vector pcDNA3.1(+), Invitrogen,Carlsbad, CA] and pLuc were prepared in our laboratory
(Margulies et al., 2001; Roos et al., 2000). The open
reading frame encoding rhesus CD4 (RhCD4) was
subcloned from a construct provided by Dr. John Rose,
via PCR with Pfu DNA polymerase (Stratagene, La Jolla,
CA) and primers to the 5V and 3V ends of the coding
region, into the vector pcDNA3.1/Zeo(+) (Invitrogen), to
create pRhCD4.
xKLuSIV cells
xKLuSIV cells were constructed by transfecting 5  106
K562 cells with 10 Ag pLuc by electroporation (Flaherty et
al., 1997; Roos et al., 2000). Cells were grown for 2 days
after transfection in R10, and then subjected to 100 Ag/mL
hygromycin (Roche Diagnostics Corporation, Indianapolis,
IN). Hygromycin-resistant cells were cloned by limiting
dilution to arrive at a single cell population that had minimal
background, yet maximal tat-stimulated luciferase activity
(Roos et al., 2000); these were identified as xKLuSIV cells
and were grown subsequently in R10 containing 100 Ag/mL
hygromycin (R10H). xKLuSIV-CCR5 cells were created
similarly, utilizing xKLuSIV cells as the precursors,
pRhCCR5, and Geneticin\ (Invitrogen-Life Technologies)
as the selecting drug at 500 Ag/mL in R10H (R10HG).
xKLuSIV-CD4 cells were created in the same fashion, with
pRhCD4 and Zeocin\ (Invitrogen) at 100 Ag/mL as the
selecting drug in R10H (R10HZ). Finally, xKLuSIV-CCR5/
CD4 cells, with xKLuSIV-CCR5 cells as precursors, were
also created similarly, then selected in R10HG with Zeocin\
(Invitrogen) at 100 Ag/mL as the third selecting drug
(R10HGZ). Expression of each molecule was confirmed
by flow cytometry (Table 1 and Fig. 2), as described below.
However, cells expressing CD4 were found to downregulate
its expression after several passages. Therefore, cells that
expressed both CD4 and CCR5 were selected and enriched
by FACS. Since maintaining these cells in culture frequently
resulted in loss of expression of either CD4 or CCR5, it was
necessary to characterize the cells each time by flow
cytometry (described below) prior to using them in experi-
ments with viruses. All experiments were always performed
with cells expressing comparable amounts of receptor on the
cell surface.
Flow cytometry
Flow cytometry was performed essentially as previ-
ously described (Carter et al., 1999). Antibodies used in
flow cytometry were monoclonal antibody 182F (anti-
CCR5; reacts against both rhesus macaque and human
CCR5; R&D Systems, Inc., Minneapolis, MN) and Leu3a
(anti-CD4; reacts with both rhesus macaque and human
CD4; Becton-Dickinson, San Jose, CA) and their
respective isotype controls conjugated to fluorescein iso-
thiocyanate (FITC) or phycoerythrin (PE) (Table 1 and
Fig. 2).
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Infection of xKLuSIV cells was performed essentially as
described for LuSIV cells (Roos et al., 2000). xKLuSIV
cells were seeded at 1.25  105 cells per well in 2 mL of
R10 in a 24-well plate, then infected with 1.873  104 cpm
reverse transcriptase activity of each virus. Four days after
inoculation, cells were pelleted and resuspended at a
concentration of 106 cells per 100 AL lysis buffer (0.5%
Triton X-100 in PBS). A 25-AL aliquot of this lysate was
assayed for luciferase activity in quadruplicate (Roos et al.,
2000). Data are reflective of one assay that was chosen as
representative of at least 3 independently conducted trials.
AOP-RANTES block
xKLuSIV cells (2.5  105 cells in R10) expressing
different receptors were incubated for 1 h at 37 -C with or
without AOP-RANTES (Gryphon Sciences, South San
Francisco, CA) at 250 or 500 ng/mL. Cells were then
challenged with 3.75  104 cpm reverse transcriptase
activity of each virus for 16 h, washed once with R10,
and resuspended in medium with half the initial concen-
tration of AOP-RANTES. Infection continued for 4 days
and the supernatants were used to perform a p27 assay (SIV
A9 kit, Beckman Coulter, Somerset, NJ) following the
manufacturer’s directions.
CD4 triggering
Virus (1.9  104 cpm reverse transcriptase activity) was
incubated with or without soluble human CD4 (sCD4) (NIH
AIDS Reagents, Rockville, MD) at 1, 5, or 10 Ag/mL for 1 h
at 37 -C. Treated virus was added to 1.25  105 xKLuSIV
cells expressing different receptor combinations. The
infection was carried for 4 days and the supernatants were
used to perform p27 assays as described above.
Neutralization assays
Virus neutralizations were performed in 96-well tissue
culture plates as previously described (Clements et al.,
1995). Briefly, fivefold serial dilutions of plasma (heat
inactivated at 56 -C) were added to each well with 50
TCID50 of virus and incubated for 1 h at 37 -C. xKLuSIV
cells expressing different receptors were then added to each
well, and the quantity of released virus was determined by
p27 assay from the tissue culture supernatants at 10 days
post-infection. mAbs 311.E, C226, and 47Awere graciously
provided by Dr. Jim Robinson from Tulane University
Medical School, New Orleans, LA. p27 levels below the
limit of detection for the assay were deemed to be the result
of complete neutralization. In addition, NP50 (50% neutral-
ization endpoint) values were calculated as previously
described from data collected in these assays (Clements et
al., 1995; Cole et al., 2001; Karber, 1931).Acknowledgments
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